Polymeric Nanoparticles for Increased Oral Bioavailability and Rapid Absorption Using Celecoxib As a Model of a Low-solubility, High-permeability Drug

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2011 Aug 25

PMID 21863477

Citations 31

Authors

Michael Morgen

Corey Bloom

Ron Beyerinck

Akintunde Bello

Wei Song

Karen Wilkinson

Rick Steenwyk

Sheri Shamblin

Affiliations

Soon will be listed here.

Abstract

Purpose: To demonstrate drug/polymer nanoparticles can increase the rate and extent of oral absorption of a low-solubility, high-permeability drug.

Methods: Amorphous drug/polymer nanoparticles containing celecoxib were prepared using ethyl cellulose and either sodium caseinate or bile salt. Nanoparticles were characterized using dynamic light scattering, transmission and scanning electron microscopy, and differential scanning calorimetry. Drug release and resuspension studies were performed using high-performance liquid chromatography. Pharmacokinetic studies were performed in dogs and humans.

Results: A physical model is presented describing the nanoparticle state of matter and release performance. Nanoparticles dosed orally in aqueous suspensions provided higher systemic exposure and faster attainment of peak plasma concentrations than commercial capsules, with median time to maximum drug concentration (Tmax) of 0.75 h in humans for nanoparticles vs. 3 h for commercial capsules. Nanoparticles released celecoxib rapidly and provided higher dissolved-drug concentrations than micronized crystalline drug. Nanoparticle suspensions are stable for several days and can be spray-dried to form dry powders that resuspend in water.

Conclusions: Drug/polymer nanoparticles are well suited for providing rapid oral absorption and increased bioavailability of BCS Class II drugs.

Citing Articles

Advancements in the Transdermal Drug Delivery Systems Utilizing Microemulsion-based Gels.

Song Y, Chen W, Yin Y, Li J, Wang M, Liu Y Curr Pharm Des. 2024; 30(35):2753-2764.

PMID: 39092731 DOI: 10.2174/0113816128305190240718112945.

Chitosan/Alginate-Based Nanoparticles for Antibacterial Agents Delivery.

Wathoni N, Herdiana Y, Suhandi C, Mohammed A, El-Rayyes A, Narsa A Int J Nanomedicine. 2024; 19:5021-5044.

PMID: 38832335 PMC: 11146614. DOI: 10.2147/IJN.S469572.

Mathematical modeling and optimization technique of anticancer antibiotic adsorption onto carbon nanocarriers.

Sumetpipat K, Baowan D, Tiangtrong P Sci Rep. 2024; 14(1):11988.

PMID: 38796555 PMC: 11127958. DOI: 10.1038/s41598-024-62483-4.

Self-micellizing solid dispersion of thymoquinone with enhanced biopharmaceutical and nephroprotective effects.

Halder S, Afrose S, Shill M, Sharmin N, Mollick P, Shuma M Drug Deliv. 2024; 31(1):2337423.

PMID: 38590120 PMC: 11005877. DOI: 10.1080/10717544.2024.2337423.

The Use of Data Mining for Obtaining Deeper Insights into the Fabrication of Prednisolone-Loaded Chitosan Nanoparticles.

Nasereddin J, Al Wadi R, Zaid Al-Kilani A, Abu Khalil A, Al Natour M, Dayyih W AAPS PharmSciTech. 2024; 25(2):38.

PMID: 38355842 DOI: 10.1208/s12249-024-02756-3.

References

Dolenc A, Kristl J, Baumgartner S, Planinsek O . Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm. 2009; 376(1-2):204-12. DOI: 10.1016/j.ijpharm.2009.04.038. View

Muller R, Keck C . Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2004; 113(1-3):151-70. DOI: 10.1016/j.jbiotec.2004.06.007. View

Curatolo W, Nightingale J, Herbig S . Utility of hydroxypropylmethylcellulose acetate succinate (HPMCAS) for initiation and maintenance of drug supersaturation in the GI milieu. Pharm Res. 2009; 26(6):1419-31. DOI: 10.1007/s11095-009-9852-z. View

Chawla G, Gupta P, Thilagavathi R, Chakraborti A, Bansal A . Characterization of solid-state forms of celecoxib. Eur J Pharm Sci. 2003; 20(3):305-17. DOI: 10.1016/s0928-0987(03)00201-x. View

Vehring R . Pharmaceutical particle engineering via spray drying. Pharm Res. 2007; 25(5):999-1022. PMC: 2292490. DOI: 10.1007/s11095-007-9475-1. View

Leuner C, Dressman J . Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000; 50(1):47-60. DOI: 10.1016/s0939-6411(00)00076-x. View

van Wijngaarden J, van Beek E, van Rossum G, van der Bent C, Hoekman K, van der Pluijm G . Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer. 2006; 43(2):433-42. DOI: 10.1016/j.ejca.2006.09.010. View

Yu L . Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001; 48(1):27-42. DOI: 10.1016/s0169-409x(01)00098-9. View

Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K . The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm. 2004; 285(1-2):135-46. DOI: 10.1016/j.ijpharm.2004.08.001. View

10.

Nasr M . In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration. AAPS PharmSciTech. 2010; 11(1):85-9. PMC: 2850489. DOI: 10.1208/s12249-009-9364-5. View

11.

Connors K . Population characteristics of cyclodextrin complex stabilities in aqueous solution. J Pharm Sci. 1995; 84(7):843-8. DOI: 10.1002/jps.2600840712. View

12.

Hauss D . Oral lipid-based formulations. Adv Drug Deliv Rev. 2007; 59(7):667-76. DOI: 10.1016/j.addr.2007.05.006. View

13.

Hancock B, Parks M . What is the true solubility advantage for amorphous pharmaceuticals?. Pharm Res. 2000; 17(4):397-404. DOI: 10.1023/a:1007516718048. View

14.

Gursoy R, Benita S . Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004; 58(3):173-82. DOI: 10.1016/j.biopha.2004.02.001. View

15.

Abdelwahed W, Degobert G, Stainmesse S, Fessi H . Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006; 58(15):1688-713. DOI: 10.1016/j.addr.2006.09.017. View

16.

Dobry D, Settell D, Baumann J, Ray R, Graham L, Beyerinck R . A Model-Based Methodology for Spray-Drying Process Development. J Pharm Innov. 2010; 4(3):133-142. PMC: 2837209. DOI: 10.1007/s12247-009-9064-4. View

17.

Friesen D, Shanker R, Crew M, Smithey D, Curatolo W, Nightingale J . Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol Pharm. 2008; 5(6):1003-19. DOI: 10.1021/mp8000793. View

18.

Hu J, Johnston K, Williams 3rd R . Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm. 2004; 30(3):233-45. DOI: 10.1081/ddc-120030422. View

19.

Paulson S, Vaughn M, Jessen S, Lawal Y, Gresk C, Yan B . Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther. 2001; 297(2):638-45. View

20.

Yang W, Tam J, Miller D, Zhou J, McConville J, Johnston K . High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm. 2008; 361(1-2):177-88. DOI: 10.1016/j.ijpharm.2008.05.003. View